Recent advances in vaccine development for herpes simplex virus types i and II

Human Vaccines and Immunotherapeutics

Volumn 9, Issue 4, 2013, Pages 729-735

  Coleman, Jeffrey L ^a,b   Shukla, Deepak ^a  

^a UNIVERSITY OF ILLINOIS   (United States)

^b Whitney Young Magnet High School   (United States)

Author keywords

Adjuvant; Asymptomatic; Humoral; Immunity; Seronegative; Seropositive; Symptomatic; T cells

Indexed keywords

DNA VACCINE; HERPES SIMPLEX VACCINE; IMMUNOVEX; LIVE VACCINE; SUBUNIT VACCINE; UNCLASSIFIED DRUG; VIRUS DNA; VIRUS GLYCOPROTEIN;

CELLULAR IMMUNITY; DNA IMMUNIZATION; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; HERPES SIMPLEX; HERPES SIMPLEX KERATITIS; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; HUMAN; IMMUNE EVASION; IMMUNE RESPONSE; IMMUNOGENICITY; NONHUMAN; REVIEW; SEX DIFFERENCE; VACCINATION; VACCINE PRODUCTION; VIRUS ENTRY; VIRUS GENOME; VIRUS LATENCY;

ADJUVANT; ASYMPTOMATIC; HUMORAL; IMMUNITY; SERONEGATIVE; SEROPOSITIVE; SYMPTOMATIC; T CELLS;

ADJUVANTS, IMMUNOLOGIC; DRUG DISCOVERY; HERPES SIMPLEX; HERPESVIRUS 1, HUMAN; HERPESVIRUS 2, HUMAN; HERPESVIRUS VACCINES; HUMANS; VACCINATION; VACCINES, ATTENUATED; VACCINES, SYNTHETIC;

EID: 84877138314     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.23289     Document Type: Review

References (51)

1. Koelle DM, Corey L. Recent progress in herpes simplex virus immunobiology and vaccine research. Clin Microbiol Rev 2003; 16:96-113; PMID:12525427; http://dx.doi.org/10.1128/CMR.16.1.96-113.2003.
2. Johnston C, Koelle DM, Wald A. HSV-2: in pursuit of a vaccine. J Clin Invest 2011; 121:4600-9; PMID:22133885; http://dx.doi.org/10.1172/JCI57148.
3. Dervillez X, Gottimukkala C, Kabbara K W, Nguyen C, Badakhshan T, Kim SM, et al. Future of an "asymptomatic" T-cell epitope-based therapeutic herpes simplex vaccine. Future Virol 2012; 7:371-8; PMID:22701511; http://dx.doi.org/10.2217/fvl.12.22.
4. Brittle EE, Friedman HM. Current herpes simplex virus vaccine approaches-a short review. US Infectious Diseases 2006; 1:13-6.
5. Shukla D, Spear PG. Herpesviruses and heparan sulfate: an intimate relationship in aid of viral entry. J Clin Invest 2001; 108:503-10; PMID:11518721.
6. Shukla D. Unraveling the cell entry mechanisms of HSV: therapeutic potential? Future Virol 2012; 7:427-30; http://dx.doi.org/10.2217/fvl.12.33.
7. Akhtar J, Shukla D. Viral entry mechanisms: cellular and viral mediators of herpes simplex virus entry. FEBS J 2009; 276:7228-36; PMID:19878306; http://dx.doi.org/10.1111/j.1742-4658.2009.07402.x.
8. Koelle DM, Wald A. Herpes simplex virus: the importance of asymptomatic shedding. J Antimicrob Chemother 2000; 45(Suppl T3):1-8; PMID:10855766; http://dx.doi.org/10.1093/jac/45.suppl-4.1.
9. Salameh S, Sheth U, Shukla D. Early events in herpes simplex virus lifecycle with implications for an infection of lifetime. Open Virol J 2012; 6:1-6; PMID:22291864; http://dx.doi.org/10.2174/1874357901206010001.
10. Bernstein DI, Stanberry LR. Herpes simplex virus vaccines. Vaccine 1999; 17:1681-9; PMID:10194823; http://dx.doi.org/10.1016/S0264-410X(98)00434-4.
11. Chentoufi AA, Kritzer E, Yu DM, Nesburn AB, Benmohamed L. Towards a rational design of an asymptomatic clinical herpes vaccine: the old, the new, and the unknown. Clin Dev Immunol 2012; 2012:187585; PMID:22548113.
12. Dundarov S, Andonov P, Bakalov B. Characterization of herpes simplex virus strains isolated from patients with various diseases. Arch Virol 1980; 63:115-21; PMID:6243918; http://dx.doi.org/10.1007/BF01320768.
13. Skinner GR, Davies JA, Dundarov S, Andonov P. Prevention of herpes genitalis by the 'Bulgarian' vaccine F.HSV-2V(PRK): preliminary clinical evidence. Croat Med J 2000; 41:378-83; PMID:11063759.
14. Wachsman M, Kulka M, Smith CC, Aurelian L. A growth and latency compromised herpes simplex virus type 2 mutant (ICP10DeltaPK) has prophylactic and therapeutic protective activity in guinea pigs. Vaccine 2001; 19:1879-90; PMID:11228357; http://dx.doi.org/10.1016/S0264-410X(00)00446-1.
15. Aurelian L. Herpes simplex virus type 2 vaccines: new ground for optimism? Clin Diagn Lab Immunol 2004; 11:437-45; PMID:15138167.
16. Watanabe D, Brockman MA, Ndung'u T, Mathews L, Lucas W T, Murphy CG, et al. Properties of a herpes simplex virus multiple immediate-early gene-deleted recombinant as a vaccine vector. Virology 2007; 357:186-98; PMID:16996101; http://dx.doi.org/10.1016/j.virol.2006.08.015.
17. van Lint AL, Torres-Lopez E, Knipe DM. Immunization with a replication-defective herpes simplex virus 2 mutant reduces herpes simplex virus 1 infection and prevents ocular disease. Virology 2007; 368:227-31; PMID:17915278; http://dx.doi.org/10.1016/j.virol.2007.08.030.
18. Dudek T, Mathews LC, Knipe DM. Disruption of the U(L)41 gene in the herpes simplex virus 2 dl5-29 mutant increases its immunogenicity and protective capacity in a murine model of genital herpes. Virology 2008; 372:165-75; PMID:18006033; http://dx.doi.org/10.1016/j.virol.2007.10.014.
19. Reszka NJ, Dudek T, Knipe DM. Construction and properties of a herpes simplex virus 2 dl5-29 vaccine candidate strain encoding an HSV-1 virion host shutoff protein. Vaccine 2010; 28:2754-62; PMID:20117270; http://dx.doi.org/10. 1016/j.vaccine.2010.01.030.
20. Dudek TE, Torres-Lopez E, Crumpacker C, Knipe DM. Evidence for differences in immunologic and pathogenesis properties of herpes simplex virus 2 strains from the United States and South Africa. J Infect Dis 2011; 203:1434-41; PMID:21498376; http://dx.doi.org/10.1093/infdis/jir047.
21. Bourne N, Bravo FJ, Francotte M, Bernstein DI, Myers MG, Slaoui M, et al. Herpes simplex virus (HSV) type 2 glycoprotein D subunit vaccines and protection against genital HSV-1 or HSV-2 disease in guinea pigs. J Infect Dis 2003; 187:542-9; PMID:12599070; http://dx.doi.org/10.1086/374002.
22. Belshe RB, Leone PA, Bernstein DI, Wald A, Levin MJ, Stapleton JT, et al.; Herpevac Trial for Women. Efficacy results of a trial of a herpes simplex vaccine. N Engl J Med 2012; 366:34-43; PMID:22216840; http://dx.doi.org/10.1056/ NEJMoa1103151.
23. Awasthi S, Lubinski JM, Friedman HM. Immunization with HSV-1 glycoprotein C prevents immune evasion from complement and enhances the efficacy of an HSV-1 glycoprotein D subunit vaccine. Vaccine 2009; 27:6845-53; PMID:19761834; http://dx.doi.org/10.1016/j.vaccine.2009.09.017.
24. Mascola JR. Herpes simplex virus vaccines-why don't antibodies protect? JAMA 1999; 282:379-80; PMID:10432037; http://dx.doi.org/10.1001/jama.282.4.379.
25. Nguyen LH, Knipe DM, Finberg RW. Replication-defective mutants of herpes simplex virus (HSV) induce cellular immunity and protect against lethal HSV infection. J Virol 1992; 66:7067-72; PMID:1331509.
26. Hosken N, McGowan P, Meier A, Koelle DM, Sleath P, Wagener F, et al. Diversity of the CD8+ T-cell response to herpes simplex virus type 2 proteins among persons with genital herpes. J Virol 2006; 80:5509-15; PMID:16699031; http://dx.doi.org/10.1128/JVI.02659-05.
27. Gyotoku T, Ono F, Aurelian L. Development of HSV-specific CD4+ Th1 responses and CD8+ cyto-toxic T lymphocytes with antiviral activity by vaccination with the HSV-2 mutant ICP10DeltaPK. Vaccine 2002; 20:2796-807; PMID:12034107; http://dx.doi.org/10.1016/S0264-410X(02)00199-8.
28. Goldsmith K, Chen W, Johnson DC, Hendricks RL. Infected cell protein (ICP)47 enhances herpes simplex virus neurovirulence by blocking the CD8+ T cell response. J Exp Med 1998; 187:341-8; PMID:9449714; http://dx.doi.org/10.1084/ jem.187.3.341.
29. Bosnjak L, Miranda-Saksena M, Koelle DM, Boadle RA, Jones CA, Cunningham AL. Herpes simplex virus infection of human dendritic cells induces apoptosis and allows cross-presentation via uninfected dendritic cells. J Immunol 2005; 174:2220-7; PMID:15699155.
30. Pollara G, Speidel K, Samady L, Rajpopat M, McGrath Y, Ledermann J, et al. Herpes simplex virus infection of dendritic cells: balance among activation, inhibition, and immunity. J Infect Dis 2003; 187:165-78; PMID:12552441; http://dx.doi.org/10.1086/367675.
31. de Bruyn G, Vargas-Cortez M, Warren T, Tyring SK, Fife KH, Lalezari J, et al. A randomized controlled trial of a replication defective (gH deletion) herpes simplex virus vaccine for the treatment of recurrent genital herpes among immunocompetent subjects. Vaccine 2006; 24:914-20; PMID:16213066; http://dx.doi.org/10.1016/j.vaccine.2005.08.088.
32. Sin J, Kim JJ, Pachuk C, Satishchandran C, Weiner DB. DNA vaccines encoding interleukin-8 and RANTES enhance antigen-specific Th1-type CD4(+) T-cell-mediated protective immunity against herpes simplex virus type 2 in vivo. J Virol 2000; 74:11173-80; PMID:11070014; http://dx.doi.org/10.1128/JVI.74.23. 11173-11180.2000.
33. Kim TW, Hung CF, Kim JW, Juang J, Chen PJ, He L, et al. Vaccination with a DNA vaccine encoding herpes simplex virus type 1 VP22 linked to antigen generates long-term antigen-specific CD8-positive memory T cells and protective immunity. Hum Gene Ther 2004; 15:167-77; PMID:14975189; http://dx.doi.org/10. 1089/104303404772679977.
34. Tengvall S, Lundqvist A, Eisenberg RJ, Cohen GH, Harandi AM. Mucosal administration of CpG oligode-oxynucleotide elicits strong CC and CXC chemokine responses in the vagina and serves as a potent Th1-tilting adjuvant for recombinant gD2 protein vaccination against genital herpes. J Virol 2006; 80:5283-91; PMID:16699008; http://dx.doi.org/10.1128/JVI.02013-05.
35. Meseda CA, Elkins KL, Merchlinsky MJ, Weir J P. Prime-boost immunization with DNA and modified vaccinia virus ankara vectors expressing herpes simplex virus-2 glycoprotein D elicits greater specific antibody and cytokine responses than DNA vaccine alone. J Infect Dis 2002; 186:1065-73; PMID:12355355; http://dx.doi.org/10.1086/344234.
36. Meseda CA, Stout RR, Weir J P. Evaluation of a needle-free delivery platform for prime-boost immunization with DNA and modified vaccinia virus ankara vectors expressing herpes simplex virus 2 glycoprotein D. Viral Immunol 2006; 19:250-9; PMID:16817767; http://dx.doi.org/10.1089/vim.2006.19.250.
37. Zhao H P, Sun JF, Li N, Sun Y, Wang Y, Qiu HJ. Prime-boost immunization using alphavirus replicon and adenovirus vectored vaccines induces enhanced immune responses against classical swine fever virus in mice. Vet Immunol Immunopathol 2009; 131:158-66; PMID:19411115; http://dx.doi.org/10.1016/j. vetimm.2009.04.003.
38. Schiffer J T, Aubert M, Weber ND, Mintzer E, Stone D, Jerome KR. Targeted DNA mutagenesis for the cure of chronic viral infections. J Virol 2012; 86:8920-36; PMID:22718830; http://dx.doi.org/10.1128/JVI.00052-12.
39. Shlapobersky M, Marshak JO, Dong L, Huang ML, Wei Q, Chu A, et al. Vaxfectin-adjuvanted plasmid DNA vaccine improves protection and immunogenic-ity in a murine model of genital herpes infection. J Gen Virol 2012; 93:1305-15; PMID:22398318; http://dx.doi.org/10.1099/vir.0.040055-0.
40. Chiuppesi F, Vannucci L, De Luca A, Lai M, Matteoli B, Freer G, et al. A lentiviral vector-based, herpes simplex virus 1 (HSV-1) glycoprotein B vaccine affords cross-protection against HSV-1 and HSV-2 genital infections. J Virol 2012; 86:6563-74; PMID:22491465; http://dx.doi.org/10.1128/JVI.00302-12.
41. Görander S, Harandi AM, Lindqvist M, Bergström T, Liljeqvist JÅ. Glycoprotein G of herpes simplex virus 2 as a novel vaccine antigen for immunity to genital and neurological disease. J Virol 2012; 86:7544-53; PMID:22553328; http://dx.doi.org/10.1128/JVI.00186-12.
42. Wizel B, Persson J, Thörn K, Nagy E, Harandi AM. Nasal and skin delivery of IC31(®)-adjuvanted recombinant HSV-2 gD protein confers protection against genital herpes. Vaccine 2012; 30:4361-8; PMID:22682292; http://dx.doi.org/10.1016/j.vac-cine.2012.02.019.
43. Pan M, Wang X, Liao J, Yin D, Li S, Pan Y, et al. Prediction and identification of potential immuno-dominant epitopes in glycoproteins B, C, E, G, and I of herpes simplex virus type 2. Clin Dev Immunol 2012; 2012:205313; PMID:22649465; http://dx.doi.org/10.1155/2012/205313.
44. Akhrameyeva NV, Zhang P, Sugiyama N, Behar SM, Yao F. Development of a glycoprotein D-expressing dominant-negative and replication-defective herpes simplex virus 2 (HSV-2) recombinant viral vaccine against HSV-2 infection in mice. J Virol 2011; 85:5036-47; PMID:21389121; http://dx.doi.org/10.1128/JVI. 02548-10.
45. Dasgupta G, Chentoufi AA, Kalantari M, Falatoonzadeh P, Chun S, Lim CH, et al. Immunodominant "asymptomatic" herpes simplex virus 1 and 2 protein antigens identified by probing whole-ORFome microarrays with serum antibodies from seropositive asymptomatic versus symptomatic individuals. J Virol 2012; 86:4358-69; PMID:22318137; http://dx.doi.org/10.1128/JVI.07107-11.
46. Shin H, Iwasaki A. A vaccine strategy that protects against genital herpes by establishing local memory T cells. Nature 2012; 491:463-7; PMID:23075848; http://dx.doi.org/10.1038/nature11522.
47. Morello CS, Kraynyak KA, Levinson MS, Chen Z, Lee KF, Spector DH. Inactivated HSV-2 in MPL/alum adjuvant provides nearly complete protection against genital infection and shedding following long term challenge and rechallenge. Vaccine 2012; 30:6541-50; PMID:22947141; http://dx.doi.org/10.1016/ j.vac-cine.2012.08.049.
48. Morello CS, Levinson MS, Kraynyak KA, Spector DH. Immunization with herpes simplex virus 2 (HSV-2) genes plus inactivated HSV-2 is highly protective against acute and recurrent HSV-2 disease. J Virol 2011; 85:3461-72; PMID:21270160; http://dx.doi.org/10.1128/JVI.02521-10.
49. Wald A, Koelle DM, Fife K, Warren T, Leclair K, Chicz RM, et al. Safety and immunogenicity of long HSV-2 peptides complexed with rhHsc70 in HSV-2 seropositive persons. Vaccine 2011; 29:8520-9; PMID:21945262; http://dx.doi.org/10.1016/j.vac-cine.2011.09.046.
50. Koelle DM, Liu Z, McClurkan CL, Cevallos RC, Vieira J, Hosken NA, et al. Immunodominance among herpes simplex virus-specific CD8 T cells expressing a tissue-specific homing receptor. Proc Natl Acad Sci U S A 2003; 100:12899-904; PMID:14566059; http://dx.doi.org/10.1073/pnas.2131705100.
51. Vagvala S P, Thebeau LG, Wilson SR, Morrison LA. Virus-encoded b7-2 costimulation molecules enhance the protective capacity of a replication-defective herpes simplex virus type 2 vaccine in immunocompetent mice. J Virol 2009; 83:953-60; PMID:18987142; http://dx.doi.org/10.1128/JVI. 02022-08.